Gene Editing Collaboration and Licensing Deals 2016-2025
Gene Editing Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025
Gene Editing Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene editing deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of gene editing deals from 2016 to 2025.
The report provides a detailed understanding and analysis of how and why companies enter gene editing deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 384 gene editing deals announced since 2016 including financial terms where available including links to online deal records of actual gene editing partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of gene editing dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in gene editing dealmaking since 2016.
Chapter 3 provides an overview of the leading gene editing deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene editing dealmaking with a brief summary followed by a comprehensive listing of gene editing deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of gene editing deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene editing technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in gene editing deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2016
• Browse gene editing collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Report scope
Gene Editing Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene editing trends and structure of deals entered into by leading biopharma companies worldwide.
Gene Editing Collaboration and Licensing Deals includes:
• Trends in gene editing dealmaking in the biopharma industry
• Directory of gene editing deal records covering pharmaceutical and biotechnology
• The leading gene editing deals by value
• Most active gene editing licensing dealmakers
Gene Editing Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2016
• Browse gene editing collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in gene editing dealmaking
2.1. Introduction
2.2. Gene editing deals over the years
2.3. Most active gene editing dealmakers
2.4. Gene editing deals by deal type
2.5. Gene editing deals by therapy area
2.6. Gene editing deals by industry sector
2.7. Deal terms for gene editing deals
2.7.1 Gene editing deals headline values
2.7.2 Gene editing deal upfront payments
2.7.3 Gene editing deal milestone payments
2.7.4 Gene editing royalty rates
Chapter 3 – Leading gene editing deals
3.1. Introduction
3.2. Top gene editing deals by value
Chapter 4 – Most active gene editing dealmakers
4.1. Introduction
4.2. Most active gene editing dealmakers
4.3. Most active gene editing deals company profiles
Chapter 5 – Gene editing contracts dealmaking directory
5.1. Introduction
5.2. Gene editing contracts dealmaking directory
Chapter 6 – Gene editing dealmaking by technology type
Deal directory
Deal directory – Gene editing deals by company A-Z
Deal directory – Gene editing deals by deal type
Deal directory – Gene editing deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Gene editing deals since 2016
Figure 2: Active gene editing dealmaking activity – 2016 - 2025
Figure 3: Gene editing deals by deal type since 2016
Figure 4: Gene editing deals by therapy area since 2016
Figure 5: Gene editing deals by industry sector since 2016
Figure 6: Gene editing deals with a headline value
Figure 7: Gene editing deals with an upfront value
Figure 8: Gene editing deals with a milestone value
Figure 9: Gene editing deals with a royalty rate value
Figure 10: Top gene editing deals by value since 2016
Figure 11: Most active gene editing dealmakers 2016 - 2025
Figure 12: Gene editing deals by technology type since 2016
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
About Current Partnering
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
- Company press releases and announcements
- SEC filings and equivalent regulatory disclosures
- Company and investor presentations
- Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
- Licensing and co-development
- Research and collaborative R&D
- Manufacturing, supply, and distribution
- Commercialisation and co-promotion
- Equity investments, joint ventures, and asset transactions
- Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
- Financial terms — including upfront payments, milestones, and royalties
- Rights allocation — development, manufacturing, and commercialization responsibilities
- Deal structure — exclusivity, territorial scope, and agreement type
- Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
- Therapy area and technology type
- Stage of development
- Asset type and deal components
- Geographic scope and exclusivity
- Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
- How financial mechanisms are defined and triggered
- How responsibilities are operationalised between parties
- How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:
- Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
- Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
- Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight
Common use cases include:
- Benchmarking comparable transactions
- Supporting valuation and deal structuring
- Preparing for negotiations
- Evaluating potential partners
- Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.
